The DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.
Infliximab for Induction and Maintenance Therapy for Ulcerative Colitis
Open accessAbstract
BACKGROUND: Infliximab, a chimeric monoclonal antibody directed against tumor necrosis factor alpha, is an established treatment for Crohn's disease but not ulcerative colitis. METHODS: Two randomized, double-blind, placebo-controlled studies--the Active Ulcerative Colitis Trials 1 and 2 (ACT 1 and ACT 2, respectively)--evaluated the efficacy of infliximab for induction and maintenance therapy in adults with ulcerative colitis. In each study, 364 patients with moderate-to-severe active ulcerative colitis despite treatment with concurrent medications received placebo or infliximab (5 mg or 10 mg per kilogram of body weight) intravenously at weeks 0, 2, and 6 and then every eight weeks through week 46 (in ACT 1) or week 22 (in ACT 2). Patients were followed for 54 weeks in ACT 1 and 30 weeks in ACT 2. RESULTS: In ACT 1, 69 percent of patients who received 5 mg of infliximab and 61 percent of those who received 10 mg had a clinical response at week 8, as compared with 37 percent of those who received placebo (P<0.001 for both comparisons with placebo). A response was defined as a decrease in the Mayo score of at least 3 points and at least 30 percent, with an accompanying decrease in the subscore for rectal bleeding of at least 1 point or an absolute rectal-bleeding subscore of 0 or 1. In ACT 2, 64 percent of patients who received 5 mg of infliximab and 69 percent of those who received 10 mg had a clinical response at week 8, as compared with 29 percent of those who received placebo (P<0.001 for both comparisons with placebo). In both studies, patients who received infliximab were more likely to have a clinical response at week 30 (P< or =0.002 for all comparisons). In ACT 1, more patients who received 5 mg or 10 mg of infliximab had a clinical response at week 54 (45 percent and 44 percent, respectively) than did those who received placebo (20 percent, P<0.001 for both comparisons). CONCLUSIONS: Patients with moderate-to-severe active ulcerative colitis treated with infliximab at weeks 0, 2, and 6 and every eight weeks thereafter were more likely to have a clinical response at weeks 8, 30, and 54 than were those receiving placebo. (ClinicalTrials.gov numbers, NCT00036439 and NCT00096655.)
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial
Hanauer, S. B., Feagan, B. G., Lichtenstein, G. R., Mayer, L. F., Schreiber, S., Colombel, J. F., Rachmilewitz, D., Wolf, D. C., Olson, A., Bao, W., et al. (2002) · The Lancet · doi:10.1016/s0140-6736(02)08512-4 · Cited by 4,169
Self-citationTargan, S. R., Hanauer, S. B., van Deventer, S. J. H., Mayer, L., Present, D. H., Braakman, T., DeWoody, K. L., Schaible, T. F., & Rutgeerts, P. J. (1997) · New England Journal of Medicine · doi:10.1056/nejm199710093371502 · Cited by 3,135
Self-citationCoated Oral 5-Aminosalicylic Acid Therapy for Mildly to Moderately Active Ulcerative Colitis
Schroeder, K. W., Tremaine, W. J., & Ilstrup, D. M. (1987) · New England Journal of Medicine · doi:10.1056/nejm198712243172603 · Cited by 3,026
Infliximab for the Treatment of Fistulas in Patients with Crohn's Disease
Present, D. H., Rutgeerts, P., Targan, S., Hanauer, S. B., Mayer, L., van Hogezand, R. A., Podolsky, D. K., Sands, B. E., Braakman, T., DeWoody, K. L., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199905063401804 · Cited by 2,752
Self-citationInfliximab Maintenance Therapy for Fistulizing Crohn's Disease
Sands, B. E., Anderson, F. H., Bernstein, C. N., Chey, W. Y., Feagan, B. G., Fedorak, R. N., Kamm, M. A., Korzenik, J. R., Lashner, B. A., Onken, J. E., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa030815 · Cited by 2,226
Self-citationCyclosporine in Severe Ulcerative Colitis Refractory to Steroid Therapy
Lichtiger, S., Present, D. H., Kornbluth, A., Gelernt, I., Bauer, J., Galler, G., Michelassi, F., & Hanauer, S. (1994) · New England Journal of Medicine · doi:10.1056/nejm199406303302601 · Cited by 1,714
Self-citationSeverity of inflammation is a risk factor for colorectal neoplasia in ulcerative colitis
Rutter, M., Saunders, B., Wilkinson, K., Rumbles, S., Schofield, G., Kamm, M., Williams, C., Price, A., Talbot, I., & Forbes, A. (2004) · Gastroenterology · doi:10.1053/j.gastro.2003.11.010 · Cited by 1,255
Faubion, W. A., Loftus, E. V., Harmsen, W. S., Zinsmeister, A. R., & Sandborn, W. J. (2001) · Gastroenterology · doi:10.1053/gast.2001.26279 · Cited by 1,144
Self-citationJärnerot, G., Hertervig, E., Friis-Liby, I., Blomquist, L., Karlén, P., Grännö, C., Vilien, M., Ström, M., Danielsson, Å., Verbaan, H., et al. (2005) · Gastroenterology · doi:10.1053/j.gastro.2005.03.003 · Cited by 1,089
Rutgeerts, P., D'Haens, G., Targan, S., Vasiliauskas, E., Hanauer, S. B., Present, D. H., Mayer, L., Van Hogezand, R. A., Braakman, T., DeWoody, K. L., et al. (1999) · Gastroenterology · doi:10.1016/s0016-5085(99)70332-x · Cited by 1,080
Self-citation
Cited by
Items 101–162 of 162
Ford, A. C., & Peyrin-Biroulet, L. (2013) · American Journal of Gastroenterology · doi:10.1038/ajg.2013.138 · Cited by 343
Adedokun, O. J., Sandborn, W. J., Feagan, B. G., Rutgeerts, P., Xu, Z., Marano, C. W., Johanns, J., Zhou, H., Davis, H. M., Cornillie, F., et al. (2014) · Gastroenterology · doi:10.1053/j.gastro.2014.08.035 · Cited by 341
Self-citationYao, D., Dong, M., Dai, C., & Wu, S. (2019) · Inflammatory Bowel Diseases · doi:10.1093/ibd/izz149 · Cited by 338
Ghosh, S., & Mitchell, R. (2007) · Journal of Crohn's and Colitis · doi:10.1016/j.crohns.2007.06.005 · Cited by 335
Allez, M., Karmiris, K., Louis, E., Van Assche, G., Ben-Horin, S., Klein, A., Van der Woude, J., Baert, F., Eliakim, R., Katsanos, K., et al. (2010) · Journal of Crohn's and Colitis · doi:10.1016/j.crohns.2010.04.004 · Cited by 334
Tumor Necrosis Factor Inhibitors for Inflammatory Bowel Disease
Nielsen, O. H., & Ainsworth, M. A. (2013) · New England Journal of Medicine · doi:10.1056/nejmct1209614 · Cited by 334
Anti-inflammatory Effects of Phosphatidylcholine
Treede, I., Braun, A., Sparla, R., Kühnel, M., Giese, T., Turner, J. R., Anes, E., Kulaksiz, H., Füllekrug, J., Stremmel, W., et al. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m704408200 · Cited by 334
Angelberger, S., Reinisch, W., Makristathis, A., Lichtenberger, C., Dejaco, C., Papay, P., Novacek, G., Trauner, M., Loy, A., & Berry, D. (2013) · American Journal of Gastroenterology · doi:10.1038/ajg.2013.257 · Cited by 330
Selvasekar, C. R., Cima, R. R., Larson, D. W., Dozois, E. J., Harrington, J. R., Harmsen, W. S., Loftus, E. V., Sandborn, W. J., Wolff, B. G., & Pemberton, J. H. (2007) · Journal of the American College of Surgeons · doi:10.1016/j.jamcollsurg.2006.12.044 · Cited by 328
Self-citationPopulation pharmacokinetic analysis of infliximab in patients with ulcerative colitis
Fasanmade, A. A., Adedokun, O. J., Ford, J., Hernandez, D., Johanns, J., Hu, C., Davis, H. M., & Zhou, H. (2009) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-009-0718-4 · Cited by 327
Self-citationAssessing Response and Loss of Response to Biological Therapies in IBD
Yanai, H., & Hanauer, S. B. (2011) · American Journal of Gastroenterology · doi:10.1038/ajg.2011.103 · Cited by 326
Self-citationHa, C., Ullman, T. A., Siegel, C. A., & Kornbluth, A. (2012) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2012.02.004 · Cited by 322
Mucosal healing in inflammatory bowel disease: impossible ideal or therapeutic target?
Rutgeerts, P., Vermeire, S., & Van Assche, G. (2007) · Gut · doi:10.1136/gut.2005.088732 · Cited by 321
Self-citationConrad, C., Di Domizio, J., Mylonas, A., Belkhodja, C., Demaria, O., Navarini, A. A., Lapointe, A.-K., French, L. E., Vernez, M., & Gilliet, M. (2018) · Nature Communications · doi:10.1038/s41467-017-02466-4 · Cited by 317
Zhou, Y., Xu, Z. Z., He, Y., Yang, Y., Liu, L., Lin, Q., Nie, Y., Li, M., Zhi, F., Liu, S., et al. (2018) · mSystems · doi:10.1128/msystems.00188-17 · Cited by 317
The tight junction in inflammatory disease: communication breakdown
Edelblum, K. L., & Turner, J. R. (2009) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2009.06.022 · Cited by 314
An Evidence-Based Systematic Review on Medical Therapies for Inflammatory Bowel Disease
Talley, N. J., Abreu, M. T., Achkar, J.-P., Bernstein, C. N., Dubinsky, M. C., Hanauer, S. B., Kane, S. V., Sandborn, W. J., Ullman, T. A., & Moayyedi, P. (2011) · American Journal of Gastroenterology · doi:10.1038/ajg.2011.58 · Cited by 310
Self-citationUngar, B., Chowers, Y., Yavzori, M., Picard, O., Fudim, E., Har-Noy, O., Kopylov, U., Eliakim, R., Ben-Horin, S., & on behalf of ABIRISK consortium (2014) · Gut · doi:10.1136/gutjnl-2013-305259 · Cited by 309
Cytokines as Therapeutic Targets in Rheumatoid Arthritis and Other Inflammatory Diseases
Siebert, S., Tsoukas, A., Robertson, J., & McInnes, I. (2015) · Pharmacological Reviews · doi:10.1124/pr.114.009639 · Cited by 307
MicroRNA Regulation of Intestinal Epithelial Tight Junction Permeability
Ye, D., Guo, S., Al–Sadi, R., & Ma, T. Y. (2011) · Gastroenterology · doi:10.1053/j.gastro.2011.07.005 · Cited by 306
Ulcerative colitis: Recent advances in the understanding of disease pathogenesis
Porter, R. J., Kalla, R., & Ho, G.-T. (2020) · F1000Research · doi:10.12688/f1000research.20805.1 · Cited by 300
Arijs, I., De Hertogh, G., Lemaire, K., Quintens, R., Van Lommel, L., Van Steen, K., Leemans, P., Cleynen, I., Van Assche, G., Vermeire, S., et al. (2009) · PLoS ONE · doi:10.1371/journal.pone.0007984 · Cited by 300
Self-citationWeber, C. R., Raleigh, D. R., Su, L., Shen, L., Sullivan, E. A., Wang, Y., & Turner, J. R. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.064808 · Cited by 298
Mor, I. J., Vogel, J. D., da Luz Moreira, A., Shen, B., Hammel, J., & Remzi, F. H. (2008) · Diseases of the Colon & Rectum · doi:10.1007/s10350-008-9364-7 · Cited by 297
Fasanmade, A. A., Adedokun, O. J., Blank, M., Zhou, H., & Davis, H. M. (2011) · Clinical Therapeutics · doi:10.1016/j.clinthera.2011.06.002 · Cited by 297
Rubin, D. T., Huo, D., Kinnucan, J. A., Sedrak, M. S., McCullom, N. E., Bunnag, A. P., Raun–Royer, E. P., Cohen, R. D., Hanauer, S. B., Hart, J., et al. (2013) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2013.06.023 · Cited by 296
Self-citationCholapranee, A., Hazlewood, G. S., Kaplan, G. G., Peyrin‐Biroulet, L., & Ananthakrishnan, A. N. (2017) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.14030 · Cited by 296
Bessissow, T., Lemmens, B., Ferrante, M., Bisschops, R., Van Steen, K., Geboes, K., Van Assche, G., Vermeire, S., Rutgeerts, P., & De Hertogh, G. (2012) · American Journal of Gastroenterology · doi:10.1038/ajg.2012.301 · Cited by 292
Self-citationDotan, I., Ron, Y., Yanai, H., Becker, S., Fishman, S., Yahav, L., Ben Yehoyada, M., & Mould, D. R. (2014) · Inflammatory Bowel Diseases · doi:10.1097/mib.0000000000000212 · Cited by 291
Cytokines, Inflammation and Colon Cancer
Klampfer, L. (2011) · Current Cancer Drug Targets · doi:10.2174/156800911795538066 · Cited by 289
Current and emerging drugs for the treatment of inflammatory bowel disease
Triantafillidis, J. (2011) · Drug Design, Development and Therapy · doi:10.2147/dddt.s11290 · Cited by 289
Orally administered L. lactis secreting an anti-TNF Nanobody demonstrate efficacy in chronic colitis
Vandenbroucke, K., de Haard, H., Beirnaert, E., Dreier, T., Lauwereys, M., Huyck, L., Van Huysse, J., Demetter, P., Steidler, L., Remaut, E., et al. (2010) · Mucosal Immunology · doi:10.1038/mi.2009.116 · Cited by 289
Hyams, J., Damaraju, L., Blank, M., Johanns, J., Guzzo, C., Winter, H. S., Kugathasan, S., Cohen, S., Markowitz, J., Escher, J. C., et al. (2012) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2011.11.026 · Cited by 286
Self-citationArdizzone, S., Cassinotti, A., Duca, P., Mazzali, C., Penati, C., Manes, G., Marmo, R., Massari, A., Molteni, P., Maconi, G., et al. (2011) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2010.12.028 · Cited by 283
Gisbert, J. P., & Chaparro, M. (2020) · Journal of Crohn's and Colitis · doi:10.1093/ecco-jcc/jjz195 · Cited by 281
Sfikakis, P. P. (2010) · Current Directions in Autoimmunity · doi:10.1159/000289205 · Cited by 275
Ankylosing spondylitis and bowel disease
Rudwaleit, M., & Baeten, D. (2006) · Best Practice & Research Clinical Rheumatology · doi:10.1016/j.berh.2006.03.010 · Cited by 275
Andersen, N. N., Pasternak, B., Basit, S., Andersson, M., Svanström, H., Caspersen, S., Munkholm, P., Hviid, A., & Jess, T. (2014) · JAMA · doi:10.1001/jama.2014.5613 · Cited by 273
Williams, J. G., Alam, M. F., Alrubaiy, L., Arnott, I., Clement, C., Cohen, D., Gordon, J. N., Hawthorne, A. B., Hilton, M., Hutchings, H. A., et al. (2016) · The Lancet Gastroenterology & Hepatology · doi:10.1016/s2468-1253(16)30003-6 · Cited by 270
Ulcerative Colitis—Diagnostic and Therapeutic Algorithms
Kucharzik, T., Koletzko, S., Kannengießer, K., & Dignaß, A. (2020) · Deutsches Ärzteblatt international · doi:10.3238/arztebl.2020.0564 · Cited by 268
Gibson, D. J., Heetun, Z. S., Redmond, C. E., Nanda, K. S., Keegan, D., Byrne, K., Mulcahy, H. E., Cullen, G., & Doherty, G. A. (2015) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2014.07.041 · Cited by 268
Exacerbation of ulcerative colitis after rituximab salvage therapy
Goetz, M., Atreya, R., Ghalibafian, M., Galle, P. R., & Neurath, M. F. (2007) · Inflammatory Bowel Diseases · doi:10.1002/ibd.20215 · Cited by 268
Treatment of inflammatory bowel disease: A review of medical therapy
Kozuch, P. L., & Hanauer, S. B. (2008) · World Journal of Gastroenterology · doi:10.3748/wjg.14.354 · Cited by 261
Self-citationSchmitt, H., Billmeier, U., Dieterich, W., Rath, T., Sonnewald, S., Reid, S., Hirschmann, S., Hildner, K., Waldner, M. J., Mudter, J., et al. (2019) · Gut · doi:10.1136/gutjnl-2017-315671 · Cited by 261
Clinical Pharmacokinetics and Use??of??Infliximab
Klotz, U., Teml, A., & Schwab, M. (2007) · Clinical Pharmacokinetics · doi:10.2165/00003088-200746080-00002 · Cited by 261
Cho, J. H., & Feldman, M. (2015) · Nature Medicine · doi:10.1038/nm.3897 · Cited by 260
Recent understanding of IBD pathogenesis: Implications for future therapies
Kucharzik, T., Maaser, C., Lügering, A., Kagnoff, M., Mayer, L., Targan, S., & Domschke, W. (2006) · Inflammatory Bowel Diseases · doi:10.1097/01.mib.0000235827.21778.d5 · Cited by 254
Clark, M., Colombel, J.-F., Feagan, B. C., Fedorak, R. N., Hanauer, S. B., Kamm, M. A., Mayer, L., Regueiro, C., Rutgeerts, P., Sandborn, W. J., et al. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.05.006 · Cited by 224
Self-citationConverging goals of treatment of inflammatory bowel disease from clinical trials and practice
Levesque, B. G., Sandborn, W. J., Ruel, J., Feagan, B. G., Sands, B. E., & Colombel, J.-F. (2015) · Gastroenterology · doi:10.1053/j.gastro.2014.08.003 · Cited by 217
Self-citationKotze, P. G., Underwood, F. E., Damião, A. O. M. C., Ferraz, J. G. P., Saad-Hossne, R., Toro, M., Iade, B., Bosques-Padilla, F., Teixeira, F. V., Juliao-Banos, F., et al. (2020) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2019.06.030 · Cited by 209
Next generation of small molecules in inflammatory bowel disease
Olivera, P., Danese, S., & Peyrin-Biroulet, L. (2017) · Gut · doi:10.1136/gutjnl-2016-312912 · Cited by 154
Ohkusa, T., Kato, K., Terao, S., Chiba, T., Mabe, K., Murakami, K., Mizokami, Y., Sugiyama, T., Yanaka, A., Takeuchi, Y., et al. (2010) · American Journal of Gastroenterology · doi:10.1038/ajg.2010.84 · Cited by 138
Infliximab in the Treatment of Anti-CTLA4 Antibody (Ipilimumab) Induced Immune-Related Colitis
Minor, D. R., Chin, K., & Kashani-Sabet, M. (2009) · Cancer Biotherapy and Radiopharmaceuticals · doi:10.1089/cbr.2008.0607 · Cited by 120
Corridoni, D., Pastorelli, L., Mattioli, B., Locovei, S., Ishikawa, D., Arseneau, K. O., Chieppa, M., Cominelli, F., & Pizarro, T. T. (2012) · PLoS ONE · doi:10.1371/journal.pone.0042067 · Cited by 118
Beigel, F., Schnitzler, F., Paul Laubender, R., Pfennig, S., Weidinger, M., Göke, B., Seiderer, J., Ochsenkühn, T., & Brand, S. (2011) · Inflammatory Bowel Diseases · doi:10.1002/ibd.21362 · Cited by 84
Caron, B., Peyrin-Biroulet, L., Pariente, B., Bouhnik, Y., Seksik, P., Bouguen, G., Caillo, L., Laharie, D., Carbonnel, F., Altwegg, R., et al. (2019) · Journal of Crohn's and Colitis · doi:10.1093/ecco-jcc/jjz088 · Cited by 60
Belmiro, C. L. R., Castelo-Branco, M. T. L., Melim, L. M. C., Schanaider, A., Elia, C., Madi, K., Pavão, M. S. G., & de Souza, H. S. P. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m807211200 · Cited by 57
De Preter, V., Arijs, I., Windey, K., Vanhove, W., Vermeire, S., Schuit, F., Rutgeerts, P., & Verbeke, K. (2012) · Inflammatory Bowel Diseases · doi:10.1002/ibd.22949 · Cited by 49
Self-citationBromke, M. A., Neubauer, K., Kempiński, R., & Krzystek-Korpacka, M. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10102203 · Cited by 39
Safety of anti-TNF treatment in liver transplant recipients: a systematic review and meta-analysis
Westerouen van Meeteren, M. J., Hayee, B., Inderson, A., van der Meulen, A. E., Altwegg, R., van Hoek, B., Pageaux, G. P., Stijnen, T., Stein, D., & Maljaars, P. W. J. (2017) · Journal of Crohn's and Colitis · doi:10.1093/ecco-jcc/jjx057 · Cited by 39
Helminth therapy (worms) for induction of remission in inflammatory bowel disease
Garg, S. K., Croft, A. M., & Bager, P. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd009400.pub2 · Cited by 39
Wang, M.-H., Mousa, O. Y., Friton, J. J., Raffals, L. E., Leighton, J. A., Pasha, S. F., Picco, M. F., Cushing, K. C., Monroe, K., Nix, B. D., et al. (2020) · Inflammatory Bowel Diseases · doi:10.1093/ibd/izz209 · Cited by 27
Metadata
- Authors
- Rutgeerts, P., Sandborn, W. J., Feagan, B. G., Reinisch, W., Olson, A., Johanns, J., Travers, S., Rachmilewitz, D., Hanauer, S. B., Lichtenstein, G. R., de Villiers, W. J. S., Present, D., Sands, B. E., & Colombel, J. F.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2005-12-08
- Volume
- 353
- Issue
- 23
- Pages
- 2462-2476
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2171297959
- Cited by
- 3,902
- References
- 33
- FWCI
- 77.98
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.